Andrea Gaedigk

List of Publications by Year
in descending order

155	9,392	36303	45317
papers	citations	51	90
		h-index	g-index

187	187	187	6536
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	<scp>PharmVar GeneFocus</scp>: <scp>SLCO1B1</scp>. Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	4.7	18
2	A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy. Archives of Women's Mental Health, 2022, 25, 355-365.	2.6	1
3	CYP2D6*9 and *41: Does the Activity Value Assigned to these Alleles Need to be Reduced to more Accurately Predict Phenotype?. Clinical Pharmacology and Therapeutics, 2022, 111, 1208-1211.	4.7	1
4	Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver. Drug Metabolism and Disposition, 2022, 50, 24-32.	3.3	6
5	Utility of the 13 Câ€pantoprazole breath test as a CYP2C19 phenotyping probe for children. Clinical and Translational Science, 2022, , .	3.1	1
6	Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy. Pharmaceutics, 2022, 14, 160.	4.5	0
7	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology and Therapeutics, 2022, 112, 959-967.	4.7	166
8	CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis. Journal of Molecular Diagnostics, 2022, 24, 337-350.	2.8	23
9	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
10	Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2022, 24, 759-768.	2.4	16
11	The Identification of Novel CYP2D6 Variants in US Hmong: Results From Genome Sequencing and Clinical Genotyping. Frontiers in Pharmacology, 2022, 13, 867331.	3.5	4
12	PharmVar GeneFocus: CYP3A5. Clinical Pharmacology and Therapeutics, 2022, 112, 1159-1171.	4.7	14
13	CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study. Pharmacogenomics, 2022, 23, 315-325.	1.3	3
14	Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. Clinical and Translational Science, 2022, 15, 1787-1795.	3.1	1
15	PharmVar GeneFocus: CYP2C19. Clinical Pharmacology and Therapeutics, 2021, 109, 352-366.	4.7	72
16	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLAâ€B Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	4.7	102
17	Retrospective Review of Pharmacogenetic Testing at an Academic Childrenâ€™s Hospital. Clinical and Translational Science, 2021, 14, 412-421.	3.1	15
18	Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Scientific Reports, 2021, 11, 4158.	3.3	12

#	Article	IF	Citations
19	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 2021, 110, 888-896.	4.7	212
20	PharmVar GeneFocus: CYP2B6. Clinical Pharmacology and Therapeutics, 2021, 110, 82-97.	4.7	108
21	CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice. Pharmacogenomics Journal, 2021, 21, 484-490.	2.0	7
22	CYP2D6 Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar. Frontiers in Pharmacology, 2021, 12, 654054.	3.5	7
23	Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population. Pharmacogenomics, 2021, 22, 323-334.	1.3	6
24	Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization. Journal of Molecular Diagnostics, 2021, 23, 577-588.	2.8	10
25	Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clinical Pharmacology and Therapeutics, 2021, 110, 542-545.	4.7	62
26	Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes. Pharmacogenomics, 2021, 22, 529-541.	1.3	10
27	Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 915-926.	0.7	2
28	PharmVar GeneFocus: CYP2C9. Clinical Pharmacology and Therapeutics, 2021, 110, 662-676.	4.7	34
29	Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX. Journal of Molecular Diagnostics, 2021, 23, 952-958.	2.8	9
30	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2021, 23, 1047-1064.	2.8	73
31	Pediatric therapeutic drug monitoring, toxicology and pharmacogenomics. , 2021, , 849-908.		0
32	Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 2021, 54, 5-17.	3.3	96
33	Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder. Frontiers in Pharmacology, 2021, 12, 743494.	3.5	4
34	The impact of the CYP2D6 â€œenhancerâ€•single nucleotide polymorphism on CYP2D6 activity. Clinical Pharmacology and Therapeutics, 2021, , .	4.7	3
35	Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New CYP2D6 Genotype. Frontiers in Psychiatry, 2021, 12, 830608.	2.6	2
36	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 50-52.	4.7	22

#	Article	IF	Citations
37	Standardizing <scp>CYP</scp>2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	3.1	353
38	PharmVar GeneFocus: CYP2D6. Clinical Pharmacology and Therapeutics, 2020, 107, 154-170.	4.7	156
39	Interrogation of <scp>CYP</scp>2D6 Structural Variant Alleles Improves the Correlation Between <scp>CYP</scp>2D6 Genotype and <scp>CYP</scp>2D6â€Mediated Metabolic Activity. Clinical and Translational Science, 2020, 13, 147-156.	3.1	42
40	Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7â€“18 Years. Clinical Pharmacology and Therapeutics, 2020, 107, 1149-1158.	4.7	6
41	PharmVar and the Landscape of Pharmacogenetic Resources. Clinical Pharmacology and Therapeutics, 2020, 107, 43-46.	4.7	50
42	The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metabolism and Disposition, 2020, 48, 1113-1120.	3.3	5
43	CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 543-551.	0.7	3
44	Long-Distance Phasing of a Tentative â€œEnhancerâ€•Single-Nucleotide Polymorphism With CYP2D6 Star Allele Definitions. Frontiers in Pharmacology, 2020, 11, 486.	3.5	10
45	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Antiâ€Inflammatory Drugs. Clinical Pharmacology and Therapeutics, 2020, 108, 191-200.	4.7	195
46	Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical and Translational Science, 2020, 13, 628-637.	3.1	12
47	Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 1-12.	0.7	7
48	Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Computational Biology, 2020, 16, e1008399.	3.2	32
49	Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genetics in Medicine, 2019, 21, 361-372.	2.4	86
50	Ageâ€•and Genotypeâ€Ðependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphateâ€Ğlucuronosyltransferases in Human Liver. Clinical Pharmacology and Therapeutics, 2019, 105, 131-141.	4.7	87
51	Pharmacogenetics: Chasing Perfection. Clinical Pharmacology and Therapeutics, 2019, 106, 265-270.	4.7	4
52	Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles. Human Mutation, 2019, 40, e37-e51.	2.5	15
53	Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles. Journal of Molecular Diagnostics, 2019, 21, 1034-1052.	2.8	55
54	Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism. Drug Metabolism and Disposition, 2019, 47, 818-831.	3.3	42

#	Article	IF	Citations
55	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenzâ€Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 726-733.	4.7	125
56	Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (CYP)</scp>2D6 Genotype and Atomoxetine Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 94-102.	4.7	152
57	The Evolution of PharmVar. Clinical Pharmacology and Therapeutics, 2019, 105, 29-32.	4.7	106
58	Pharmacogene Variation Consortium Gene Introduction: <scp>NUDT15</scp>. Clinical Pharmacology and Therapeutics, 2019, 105, 1091-1094.	4.7	45
59	The Case for Pharmacogeneticsâ€Guided Prescribing of Codeine in Children. Clinical Pharmacology and Therapeutics, 2019, 105, 1300-1302.	4.7	12
60	Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection. Pharmacogenomics, 2019, 20, 9-20.	1.3	9
61	CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics, 2019, 20, 3-8.	1.3	5
62	Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical Pharmacology and Therapeutics, 2019, 105, 1501-1512.	4.7	19
63	Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. Journal of Clinical Pharmacology, 2018, 58, 823-833.	2.0	33
64	Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clinical Pharmacokinetics, 2018, 57, 1325-1336.	3.5	16
65	Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metabolism and Disposition, 2018, 46, 888-896.	3.3	42
66	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777.	4.7	244
67	Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics, 2018, 19, 197-212.	1.3	4
68	Variants in the CYP2B6 3â€²UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs. Clinical Pharmacology and Therapeutics, 2018, 104, 130-138.	4.7	21
69	Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. PM and R, 2018, 10, 235-243.	1.6	24
70	Precision medicine: does ethnicity information complement genotype-based prescribing decisions?. Therapeutic Advances in Drug Safety, 2018, 9, 45-62.	2.4	58
71	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clinical Pharmacology and Therapeutics, 2018, 103, 399-401.	4.7	335
72	Ten Yearsâ€™ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. Journal of Personalized Medicine, 2018, 8, 15.	2.5	110

#	Article	IF	Citations
73	PASSPORT-seq: A Novel High-Throughput Bioassay to Functionally Test Polymorphisms in Micro-RNA Target Sites. Frontiers in Genetics, 2018, 9, 219.	2.3	9
74	CYP2D6 genotype analysis of a Thai population: platform comparison. Pharmacogenomics, 2018, 19, 947-960.	1.3	16
75	Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine, 2017, 19, 69-76.	2.4	365
76	Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. Drug Metabolism and Disposition, 2017, 45, 216-223.	3.3	74
77	Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics, 2017, 18, 433-443.	1.3	18
78	In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report. Pharmacogenomics, 2017, 18, 427-431.	1.3	5
79	Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 265-274.	2.5	43
80	Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver. Drug Metabolism and Disposition, 2017, 45, 1044-1048.	3.3	25
81	Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Frontiers in Pharmacology, 2017, 8, 347.	3.5	18
82	Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy. Frontiers in Pharmacology, 2017, 8, 402.	3.5	21
83	Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. Journal of Pediatric Pharmacology and Therapeutics, 2016, 21, 224-232.	0.5	5
84	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Frontiers in Pharmacology, 2016, 7, 111.	3.5	32
85	Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Human Mutation, 2016, 37, 315-323.	2.5	86
86	Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. Npj Genomic Medicine, 2016, 1, 15007.	3.8	93
87	Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Pharmacogenomics, 2016, 17, 1291-1293.	1.3	4
88	Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. Drug Metabolism and Disposition, 2016, 44, 1070-1079.	3.3	23
89	CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics, 2016, 17, 259-275.	1.3	38
90	Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. Drug Metabolism and Disposition, 2016, 44, 948-958.	3.3	37

#	Article	IF	Citations
91	Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (United States), 2016, 95, e2473.	1.0	18
92	SNP genotyping using TaqManÂ® technology: the CYP2D6*17 assay conundrum. Scientific Reports, 2015, 5, 9257.	3.3	24
93	CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification. Journal of Molecular Diagnostics, 2015, 17, 740-748.	2.8	38
94	CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6*15 and *35 Genotyping. Frontiers in Pharmacology, 2015, 6, 312.	3.5	13
95	Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization. Current Drug Metabolism, 2014, 15, 218-232.	1.2	147
96	Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics, 2014, 15, 1947-1962.	1.3	39
97	Resolution of a clinical AmpliChip CYP450 Testâ„¢ no call: discovery and characterization of novel CYP2D6*1 haplotypes. Pharmacogenomics, 2014, 15, 1175-1184.	1.3	11
98	Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 TestÂ® no-call in the clinical setting. Clinical Chemistry and Laboratory Medicine, 2014, 52, 799-807.	2.3	15
99	CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics, 2014, 15, 1055-1058.	1.3	7
100	CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics, 2014, 15, 407-410.	1.3	9
101	Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Human Molecular Genetics, 2014, 23, 268-278.	2.9	101
102	Population Pharmacokinetics of Oral Baclofen in Pediatric Patients withÂCerebral Palsy. Journal of Pediatrics, 2014, 164, 1181-1188.e8.	1.8	29
103	Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Medical Genetics, 2013, 14, 20.	2.1	42
104	Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics, 2013, 14, 261-276.	1.3	42
105	High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. Pharmacogenomics, 2013, 14, 913-922.	1.3	10
106	Complexities ofCYP2D6gene analysis and interpretation. International Review of Psychiatry, 2013, 25, 534-553.	2.8	188
107	Pharmacogenetics in American Indian populations. Pharmacogenetics and Genomics, 2013, 23, 403-414.	1.5	54
108	CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity. FASEB Journal, 2013, 27, 663.6.	0.5	0

#	Article	IF	Citations
109	Impact of development and genetic variation on human hepatic CYP2B6 expression and activity.. FASEB Journal, 2013, 27, 270.1.	0.5	0
110	CYP2D6 update. Pharmacogenetics and Genomics, 2012, 22, 692-694.	1.5	19
111	In Silico and In Vitro Identification of MicroRNAs That Regulate Hepatic Nuclear Factor 4Î± Expression. Drug Metabolism and Disposition, 2012, 40, 726-733.	3.3	79
112	The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiology of Aging, 2012, 33, 2160-2171.	3.1	68
113	CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics, 2012, 13, 91-111.	1.3	66
114	Detection and characterization of the CYP2D6*9x2 gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-calls. Pharmacogenomics, 2011, 12, 1617-1622.	1.3	17
115	Variability in drug metabolizing enzyme activity in HIV-infected patients. European Journal of Clinical Pharmacology, 2010, 66, 475-485.	1.9	80
116	Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations. European Journal of Clinical Pharmacology, 2010, 66, 859-864.	1.9	28
117	Elucidation of CYP2D6 Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population. Annals of Human Genetics, 2010, 74, 340-350.	0.8	53
118	Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants. Frontiers in Pharmacology, 2010, 1, 121.	3.5	58
119	UGT2B17 and SULT1A1 gene copy number variation (CNV) detection by LabChip microfluidic technology. Clinical Chemistry and Laboratory Medicine, 2010, 48, 627-33.	2.3	4
120	Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Research, 2010, 20, 1020-1036.	5.5	231
121	CYP2D7â€“2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics, 2010, 11, 43-53.	1.3	63
122	Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. European Journal of Clinical Pharmacology, 2009, 65, 97-100.	1.9	17
123	The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. European Journal of Clinical Pharmacology, 2008, 64, 465-475.	1.9	56
124	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genetics in Medicine, 2008, 10, 720-729.	2.4	48
125	Evaluation of a [¹³C]â€Ðextromethorphan Breath Test to Assess CYP2D6 Phenotype. Journal of Clinical Pharmacology, 2008, 48, 1041-1051.	2.0	31
126	Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Canadian Family Physician, 2007, 53, 33-5.	0.4	125

#	Article	IF	Citations
127	Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet, The, 2006, 368, 704.	13.7	582
128	Variability of CYP2J2 Expression in Human Fetal Tissues. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 523-532.	2.5	47
129	Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessiveâ€“Compulsive Disorder. Neuropsychopharmacology, 2006, 31, 1274-1285.	5.4	43
130	Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N -Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2006, 50, 1130-1135.	3.2	57
131	CYP2D6*36GENE ARRANGEMENTS WITHIN THECYP2D6LOCUS: ASSOCIATION OFCYP2D6*36WITH POOR METABOLIZER STATUS. Drug Metabolism and Disposition, 2006, 34, 563-569.	3.3	89
132	COMMENTS ON HOSKINS ET AL. [(2005) DRUG METAB DISPOS 33:1564â€“1565]: Fig. 1.. Drug Metabolism and Disposition, 2006, 34, 504-505.	3.3	3
133	Limited Association of the 2988g>a Single Nucleotide Polymorphism with CYP2D6*41 in Black Subjects. Clinical Pharmacology and Therapeutics, 2005, 77, 228-230.	4.7	26
134	Identification of CYP2D6 impaired functional alleles in Mexican Americans. European Journal of Clinical Pharmacology, 2005, 61, 797-802.	1.9	35
135	Variability of CYP3A7 Expression in Human Fetal Liver. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 626-635.	2.5	122
136	CYP2D7 splice variants in human liver and brain: Does CYP2D7 encode functional protein?. Biochemical and Biophysical Research Communications, 2005, 336, 1241-1250.	2.1	31
137	Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clinical Pharmacology and Therapeutics, 2004, 75, 163-171.	4.7	17
138	Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clinical Pharmacology and Therapeutics, 2004, 76, 536-544.	4.7	134
139	Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects. Clinical Pharmacology and Therapeutics, 2003, 73, 575-576.	4.7	25
140	CYP2D6 Poor Metabolizer Status Can Be Ruled Out by a Single Genotyping Assay for the â^'1584G Promoter Polymorphism. Clinical Chemistry, 2003, 49, 1008-1011.	3.2	70
141	Genetic Heterogeneity in the rRNA Gene Locus of Trichophyton tonsurans. Journal of Clinical Microbiology, 2003, 41, 5478-5487.	3.9	48
142	Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine. Drug Metabolism and Disposition, 2002, 30, 595-601.	3.3	56
143	Unique CYP2D6 activity distribution and genotypeâ€phenotype discordance in black Americans. Clinical Pharmacology and Therapeutics, 2002, 72, 76-89.	4.7	178
144	Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Canadian Journal of Physiology and Pharmacology, 2001, 79, 841-847.	1.4	57

#	Article	IF	Citations
145	Effects of Oral Vitamin K on S- and R-Warfarin Pharmacokinetics and Pharmacodynamics: Enhanced Safety of Warfarin as a CYP2C9 Probe. Journal of Clinical Pharmacology, 2001, 41, 715-722.	2.0	26
146	Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N -acetyltransferase-2, and xanthine oxidase with the â€³Cooperstown cocktailâ€• Clinical Pharmacology and Therapeutics, 2000, 68, 375-383.	4.7	125
147	Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clinical Pharmacology and Therapeutics, 1999, 66, 535-541.	4.7	17
148	Structural characterization of human aryl sulphotransferases. Biochemical Journal, 1999, 337, 337-343.	3.7	33
149	Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics and Genomics, 1999, 9, 669???682.	5.7	41
150	Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics and Genomics, 1999, 9, 669-682.	1.5	142
151	NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics and Genomics, 1998, 8, 305-313.	5.7	82
152	Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics and Genomics, 1998, 8, 15-26.	5.7	281
153	Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics and Genomics, 1998, 8, 403-410.	5.7	66
154	Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics and Genomics, 1998, 8, 325-333.	5.7	85
155	Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 1990, 347, 773-776.	27.8	345